Life-threatening complications of streptococcal sepsis: a PICU contemporary series
Journal of Anesthesia, Analgesia and Critical Care volume 1, Article number: 24 (2021)
Life-threatening streptococcal sepsis nowadays represents an uncommon event in previously healthy infants and children. Critically ill patients suffering from severe streptococcal sepsis complications may present with pre-antibiotic era clinical pictures and require a timely clinical approach to achieve restitutio ad integrum.
We report a series of four patient groups affected by an uncommon life-threatening streptococcal sepsis, each of them exhibiting some distinct features. Streptococcus Agalactiae sepsis was associated with cerebral thrombotic/ischaemic lesions, whereas severe cardiogenic shock was prominent in the Streptococcus Viridans group; Streptococcus Faecalis and β-hemolytic group A Streptococcus patients mostly reported lung complications.
Previous antibiotic treatments should not delay aggressive treatment in the intensive care setting. Early diagnostic suspicion, as well as appropriate and aggressive treatment provided within an intensive care setting are crucial for the clinical outcome.
We report a series of 15 consecutive cases of life-threatening sepsis complications in previously healthy infants/children caused by different streptococcal strains: Streptococcus Agalactiae (4 pts); Streptococcus Faecalis (3 pts); Streptococcus Viridans (4 pts); and Streptococcus Pyogenes (4 pts) (Table 1).
Differently from multi-resistant Gram-negative bacteria, antibiotic susceptibility did not represent the main problem to deal with. Immunosuppressed or onco-hematological patients are increasingly admitted to pediatric ICUs, while severe sepsis/septic shock in previously healthy children is decreasing in developed countries . Though rarely recorded, compared to the past, streptococci-infected immunocompetent patients may require PICU admission because of serious life-threatening conditions.
Streptococcus Agalactiae (Table 1; A1–4)
Patients with S. Agalactiae (group B Streptococcus, GBS) sepsis showed a marked cerebrovascular tropism, consistent with small vessel inflammatory involvement. Brain imaging showed different patterns of cerebrovascular damage (Fig. 1; A1–4), including severe ischaemic lesions. In case A1, a cerebral CT scan documented multiple cortical and subcortical ischaemic lesions in the left frontoparietal regions; marked brain edema was also present. A subsequent brain MRI demonstrated an almost complete thrombosis of the superior sagittal sinus with a serious compromise of the entire left cerebral hemisphere. In patient A3, a CT scan showed large ischemic cortical and subcortical lesions in the left temporal region, consequent to thrombosis of the middle cerebral artery.
None of these cases reported a positive family history for thrombophilia, and congenital hypercoagulability screening (protein C and S levels, homocysteine level, genotyping for factor V Leiden and prothrombin 20210GA mutation) resulted negative. Antiphospholipid antibodies panel was negative too, as well as the organic and aminoacidic screening.
High level respiratory and hemodynamic support was required in three patients. CSF cultures grew S. Agalactiae, fully susceptible to common antimicrobials. In three of the four described cases, despite multiple lesions, the clinical and neurological outcome was very favourable, whereas one infant (A4) developed marked cerebral edema and brain tissue herniation outside the cranial vault, due to which the parents asked for withdrawal of care.
Streptococcus Faecalis (Table 1; B1–3)
Patients with S. Faecalis sepsis showed a marked pulmonary tropism in our experience. Three infants were consecutively admitted to our PICU, presenting with high-grade fever, tachypnea and worsening dyspnea. Standard chest X-rays and lung ultrasound showed alveolar consolidations and pleural effusions. Microbiologic analysis of samples obtained from the lower respiratory tract and blood cultures revealed S. Faecalis infection. Patient B3, because of documented massive pleural effusion, underwent VATS procedure and non-invasive ventilation, while younger patients underwent intubation and ventilatory support due to severe upper airway obstruction (cystic lymphangioma) (Fig. 1B). Respiratory support together with combination antibiotic therapy successfully resolved both pulmonary and systemic symptoms in all cases.
Streptococcus Viridans (Table 1; C1–4)
Patients with S. Viridans sepsis showed a marked cardiovascular tropism. This patient subgroup presented with cardiovascular dysfunction requiring immediate haemodynamic support: tachycardia with severe hypotension, as well as external and internal jugular vein enlargement with increasing central venous pressure (CVP) were demonstrated on admission.
Standard chest radiographs revealed cardiac shape enlargement, and a right pleural effusion was also documented in case C1. 2D cardiac ultrasound revealed a severe global hypokinesia with a low ejection fraction (EF) despite fluid challenge and inotropic support with dobutamine. Enoximone was added to support cardiac contractility and a gradual improvement of the cardiac function was observed in the following 72 h, with increasing EF up to 50%. Cardiac enzymes (especially troponin and CK-MB) were increased, reflecting cardiac injury consistent with myocardial stunning. After blood cultures, a broad-spectrum antibiotic therapy was started including ceftriaxone and ampicillin. Purpuric lesions were noticed on the skin, mimicking a meningococcal infection (Fig. 1C). A severe coagulation impairment was also documented evolving into overt DIC together with a severe protein C deficiency. Fresh frozen plasma, antithrombin and activated protein C were given, achieving progressive improvement.
Case C3 presented a febrile illness with hypotension and heart systolic murmur. After 36 h, the cardiorespiratory status worsened: heart murmur evidence was increased, and CVP was high despite diuretic treatment. A 2D cardiac ultrasound showed hyperechogenic findings of the mitral valve. A moderate-to-severe valve insufficiency was documented and pre-existing congenital mitral valve cleft was hypothesised. Moderate pulmonary hypertension together with tricuspid regurgitation was also present. The child was referred to the heart surgery department after 6 days from PICU admission.
Case C4 presented as sudden severe heart failure, thereby revealing a true meningitis-septic shock picture: dobutamine and milrinone were given to improve myocardial contractility.
Streptococcus Pyogenes. (Table 1; D1–4)
These patients showed both respiratory and systemic involvement: they were consecutively admitted to PICU for high-grade fever and worsening dyspnea.
Case D2 underwent tracheal intubation due to severe respiratory failure. No breath sounds were audible on the left hemithorax. A chest X-ray revealed a large pleural effusion; after drainage, respiratory conditions progressively deteriorated. The patient developed bilateral lung consolidations, anterior left pneumothorax and bronchopleural fistula, all of them refractory to different ventilatory strategies. Due to relapsing air-leaks, a single-lung ventilation mode was undertaken, achieving a progressive clinical and respiratory recovery (Fig. 1D).
In case D3, a young child presented with refractory hypoxemia and hypotension, evolving into cathecolamine-resistant septic shock. High-level vasoactive support was required, due also to marked LV function impairment, including multiple inotropic drugs. Very low PC levels were detected (8% nv) with peripheral ischemic lesions, requiring IV replacement. A 7-day course of CVVHDF was introduced; the child improved and could be discharged from PICU on day 12.
All children admitted to PICU of a university-affiliated teaching hospital [Policlinico Universitario Agostino Gemelli] between 2000 and 2015 with laboratory-proven streptococcal sepsis/meningitis were included. Children with streptococcal isolates were identified by using the principal author’s database that registered every PICU admission. Age, length of PICU stay, PRISM-II, complications, GOS, and mortality were recorded. Ethics approval for this review was obtained from the Clinical Research Ethics Committee of our University. The bacteria were identified using conventional diagnostic methodology from specimens including blood cultures, cerebrospinal fluids, pleural aspirates, and tracheal aspirates. The diagnostic procedures were performed in the same microbiology laboratory with standardised procedures and equipment.
We present 15 cases of streptococcal sepsis complication treated in a PICU setting. Pneumococcal sepsis patients have not been considered in this series. The rarity of the clinical presentation warrants comments regarding both the occurrence and the intensive care approach. Epidemiological and intensive care management issues are discussed on a group-by-group basis.
Regarding Streptococcus agalactiae (GBS), following the CDC 2002 Guidelines recommending a universal screening for maternal rectovaginal GBS colonisation at 35–37 weeks of gestation, a clear change in the epidemiology of S. Agalactiae occurred, with a marked decrease in the prevalence of early onset GBS disease (2.0 per 1000 live births in 1990; 0.6 per 1000 by 2001–2002; 0.3 per 1000 in 2004) [2,3,4]. On the other hand, only a mild modification of the late-onset disease incidence was registered during the years 1996–2004 in the UK and, for the first time in 2003, the rate of late-onset disease overcame the one of early-onset disease [5, 6]. Cerebrovascular complications induced by S. Agalactiae late-onset sepsis are not well described, though an increased prevalence of meningitis is acknowledged. The occurrence of cerebral arteries thrombotic/ischaemic lesions and cerebral venous sinuses thrombosis in association with a purulent meningitis/septic shock have been described elsewhere, but they were rarely caused by neonatal Streptococcus agalactiae (group B streptococcus, GBS) infection, as in the present series. A rapidly progressive thrombotic occlusion of cerebral venous sinuses is associated with fatal cerebral vascular tamponade. Clinical suspicion is of paramount importance, while head CT scan may result falsely negative in up to 16% of patients . The emergency intervention is aimed at maintaining venous outflow patency, despite the impending risk of intracranial bleeding. Despite the risk of further hemorrhagic complications, intravenous unfractionated heparin (UFH) anticoagulation in association with antithrombin replacement was performed because of severe compromised cerebral condition. The neonate also needed cardiorespiratory support to improve cerebral perfusion. Protein C, protein S and antithrombin deficiency are known causes of thrombosis. However, it is more likely that depressed levels of protein C, protein S and antithrombin in our patient were related to the early consumption of these factors by the acute cerebral venous infarction and/or by the septicaemic state, rather than a cause of thrombosis. No randomised controlled trials in infants and children could support such a therapeutic choice, and even in adults there is no clear evidence [8, 9]. Consequently, despite the cerebral venous bleeding, a schedule of UFH followed by a 3-month course of low-molecular-weight heparin (LMWH) was given [7, 10]. In a large multicenter Canadian study, the incidence of cerebral sinovenous thrombosis (CSVT) was 0.67/100,000 children/year, 43% of whom were under 1 month of age; CSVT may cause cerebral venous infarction and hemorrhage because of occluded venous outflow. As a whole, prothrombotic risk factors are present in 39 to 54% of cases.
Regarding Streptococcus faecalis, literature highlighted a rising incidence of enterococcal infections during the last years, not only among adult patients but also among hospitalised patients of neonatal/paediatric intensive care and onco-haematological units [11,12,13,14]. Although many genetically different subtypes have been identified, E. faecalis and E. faecium represent the two main species causing most human enterococcal infections. These agents represent a large group of gram-positive natural inhabitants of the human gastrointestinal tract: possible clinical presentations of enterococcal infection include intra-abdominal infections, endocarditis, primary bacteremia, urinary tract infections and, less frequently, pneumonia, meningitis and osteomyelitis (especially in immunocompromised hosts). Only a few cases of E. faecalis thoracic empyema have been reported in adults. The occurrence of enterococcal sepsis followed by a pleural empyema in a previously healthy child is almost exceptional. Although enterococcal empyema is rare, its occurrence has been previously linked to intra-abdominal infections, and it is associated with a high mortality (41%) . Numerous evidence shows that the majority of enterococcal-associated infections of the lower respiratory tract have a complicated course, including the development of lung abscess, pleural empyema, respiratory failure and cardiovascular instability. Therefore, Enterococci should be considered as potential cause of severe, unresolved pneumonia. It appears of importance to avoid a prolonged course of invasive mechanical ventilation following a high-intensity antibiotic therapy. For this reason, in the case reported above, following the VATS procedure, we decided to introduce the NIV technique early, to minimise the risk of pulmonary-systemic superinfections.
Viridans streptococci (VS) represent a heterogeneous group of streptococcal species, which are part of the normal flora of human oral cavity, gastrointestinal tract and female genital tract. Infections usually result from spread of the organisms outside their normal habitat. Strains of Viridans streptococci are known to be the most common etiologic agents in bacterial endocarditis, mainly in patients with abnormal cardiac structure [16, 17]. Immunocompromised patients with VS bacteremia may develop shock, rash and respiratory distress similar to ARDS. VS may account for up to 25–30% of bacteremic episodes in patients with malignancies; VS bacteremia should be suspected in neutropenic children, especially in the presence of mucositis [18, 19]. Viridans streptococci shock syndrome (VSSS) has been defined as hypotension requiring inotropic support . VS have been frequently described as a cause of bacteremia, and VSSS develops in up to 18% of VS bacteremia in children with cancer or SCT recipients. Infection of immunocompetent individuals is generally rare . Although primary pneumonia due to Viridans streptococci has rarely been described, published reports documented recovery of these organisms in specimens of empyema and lung abscess, whereas VS septicaemia appears exceptional [22,23,24]. We observed a severe cardiac involvement with septic shock and consumption coagulopathy due to VS infection. Cardiac function impairment resembling a “cardiac stunning” picture is rarely present at onset of septic shock. In the two patients reported, after failed initial preload optimisation and dobutamine titration, a inotropic rescue with enoximone/milrninone was performed. These agents selectively inhibit phosphodiesterase III isoenzyme in both cardiac and vascular muscle, which is necessary for the breakdown of 3′5′-cyclic adenosine monophosphate (cAMP) . Due to the severity of clinical presentation, recombinant APC infusion was started, achieving coagulative status control . Though S. Viridans represents a known agent of infective endocarditis, a severe sepsis complicating pneumonia with cardiac valve involvement is unusual. All patients were empirically treated with third generation cephalosporins and amikacin before susceptibility testing was available, and recovered without complications.
Concerning Streptcoccus Pyogenes invasive disease, an increased incidence has been reported during the last years . The incidence of invasive S. Pyogenes disease in Italy is 0.38/100,000 (3/100,000 in Europe), with most cases among older patients (only 24% of cases in the 0–17 years old group) . Overall, 8% of patients with Streptococcus Pyogenes infection develop necrotizing fasciitis and 13% evolve to streptococcal toxic shock syndrome (STSS), with an incidence rising to 50% among cases of necrotizing fasciitis. The only clinical manifestation showing a higher prevalence in children < 10 years old is meningitis (2% of overall cases). Invasive group A Streptococcus (GAS) infections have been reported in all age groups, including sepsis, bacteremic pneumonia, puerperal sepsis, septic scarlet fever, scarlatina maligna, erysipelas, necrotizing fasciitis, gangrene, myositis and streptococcal toxic shock syndrome [29,30,31]. A rapid and fatal course has been described even in the immunocompetent host, with a mortality rate of 7-58% . Several risk factors have been associated with invasive GAS infection, in particular VZV co-infection and the use of nonsteroidal anti-inflammatory drugs . Though invasive GAS infections are alarmingly increasing worldwide, an acute respiratory distress syndrome caused by GAS has been rarely described in pediatrics. Despite non-staphylococcal pneumatoceles being described in childhood, reports of GAS pneumatoceles are extremely rare. In our case, a GAS pneumonia and pleural empyema rapidly progressed to ARDS. Pneumothorax and a broncho-pleural fistula complicated the ventilatory management. Failing of conventional therapies (gentle conventional ventilation, surfactant instillation) led to the adoption of a single lung ventilation. Apart from surgical indications, lung isolation may be appropriate even in unilateral lung disease (e.g., lung abscess, bronchopleural fistula, severe one-sided bullous disease, pulmonary hemorrhage) [34,35,36]. In children, due to the small tracheal dimensions, balloon-tipped bronchial blockers, wire-guided endobronchial blocker, UniventTM tubes, double-lumen tubes and selective mainstem bronchial intubations with a conventional endotracheal tube may be chosen [37,38,39]. Single lung ventilation is often complicated by the persistent collapse of the unventilated lung and by the obstruction of the right upper lobe in case of right-sided intubation. For these reasons, only time-limited applications can be recommended. In our case, a 36-h single lung ventilation resulted a safe procedure and allowed bilateral lung ventilation restoration. Unilateral lung disease represents a challenge in ventilatory management because of the asymmetry in lung mechanics. Conventional support may fail to produce adequate gas exchange and may cause further deterioration. In those circumstances, independent lung ventilation allowing different mean pressures in each lung may represent a valid strategy. Alternatively, the most compromised lung may be treated with HFOV, while the contralateral is conventionally supported. In children, due to the small tracheal dimensions, unilateral lung ventilation may represent a valid alternative.
Streptococcal sepsis remains diffusely present among the pediatric population, while severe and life-threatening cases have become consistently rarer in developed countries. Even in previously healthy infants/children, in the absence of antibiotic-resistant streptococcal species, a rapidly evolving picture of severe sepsis and septic shock may occur. Emergency physicians and intensivists should be aware of these uncommon complications, which require a timely cardiorespiratory support as well as high-dose intravenous antimicrobials. As in the presented experience, only a highly individualised approach could achieve a significant improvement of the patient’s clinical status and thereby result in a favourable outcome.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Acute respiratory distress syndrome
Cyclic adenosine monophosphate
Cerebral venous sinus thrombosis
Central venous pressure
Continuous veno-venous hemodiafiltration
Disseminated intravascular coagulation
Group A streptococcus
Group B streptococcus
Glasgow outcome scale
High-frequency oscillatory ventilation
Intensive care unit
Low molecular weight heparin
Magnetic resonance imaging
Pediatric intensive care unit
Project Resources Information System for Management II
Streptococcal toxic shock syndrome
Viridans streptococcal shock syndrome
Varicella zoster virus
Carcillo JA (2006) What’s new in Pediatric Intensive Care. Crit Care Med 34(9 Suppl):S183–S190
Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A (2002) CDC Prevention of perinatal group B streptococcal disease: revised guidelines from CDC. MMWR Morb Mortal Wkly Rep 51:11
Kainer M, McCauley T, Craig AS (2002) Prevention of early-onset group B streptococcal disease in newborn. Obset Gynecol. 100:1405–1412
Law MR, Palomaki G, Alfirevic Z, Gilbert R, Heath P, McCartney C, Reid T, Schrag S (2005) The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society. J Med Screen. 12(2):60–68. https://doi.org/10.1258/0969141053908366
Heath PT, Balfour G, Weisner AM, Efstratiou A, Lamagni TL, Tighe H, O’Connell LAF, Cafferkey M, Verlander NQ, Nicoll A, McCartney AC (2004) Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet. 363(9405):292–294. https://doi.org/10.1016/S0140-6736(03)15389-5
Centers for Disease Control and Prevention (CDC) (2005) Early-Onset and Late-Onset Neonatal Group B Streptococcal Disease: United States, 1996-2004. MMWR Morb Mortal Wkly Rep 54:1205–1208
DeVeber G, Andrew M, Adams C et al (2001) Cerebral sinovenous thrombosis in children. New Engl J Med 345(6):417–423. https://doi.org/10.1056/NEJM200108093450604
Einhaupl KM, Villringer A, Meister W et al (1991) Heparin treatment in sinus venous thrombosis. Lancet 338(8767):597–600. https://doi.org/10.1016/0140-6736(91)90607-Q
De Bruijn SFTM, Stam J (1999) Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 30(3):484–488. https://doi.org/10.1161/01.STR.30.3.484
Heller C, Heinecke A, Junker R, Knöfler R, Kosch A, Kurnik K, Schobess R, von Eckardstein A, Sträter R, Zieger B, Nowak-Göttl U, the Childhood Stroke Study Group (2003) Cerebral venous thrombosis in children: A multifactorial origin. Circulation 108(11):1362–1367. https://doi.org/10.1161/01.CIR.0000087598.05977.45
Simjee S, Gill MJ (1997) Gene transfer, gentamicin resistance and enterococci. J Hosp Infect 36(4):249–259. https://doi.org/10.1016/S0195-6701(97)90051-7
Christie C, Hammond J, Reising S, Evans-Patterson J (1994) Clinical and molecular epidemiology of enterococcal bacteremia in a pediatric teaching hospital. J Pediatr. 125(3):392–399. https://doi.org/10.1016/S0022-3476(05)83282-2
Richards MJ, Edwards JR, Culver DH, Gaynes RP (1999) Nosocomial infections in pediatric intensive care units in the United States. Pediatrics 103(4):e39. https://doi.org/10.1542/peds.103.4.e39
Sohn AH, Garrett DO, Sinkowitz-Cochran RL, Grohskopf LA, Levine GL, Stover BH, Siegel JD, Jarvis WR, Pediatric Prevention Network (2001) Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the first national point-prevalence survey pediatric prevention network. J Pediatr 139(6):821–827
Tu CY, Hsu WH, Hsia TC, Chen HJ, Chiu KL, Hang LW, Shih CM (2006) The changing pathogens of complicated parapneumonic effusions or empyemas in a medical intensive care unit. Intensive Care Med 32(4):570–576. https://doi.org/10.1007/s00134-005-0064-7
Johnson CC, Tunkel AR 1995. Viridans streptococci and groups C and G streptococci. In: Mandell GL, Douglas RG Jr, Bennett JE (eds) Principles and Practice of Infectious Diseases, 4th edn. Churchill Livingstone, New York., pp 1786–1799
Husain E, Whitehead ART, Castell A et al (2005) Viridans Streptococci bacteremia in children with malignancy: relevance of species identification and penicillin susceptibility. Pediatr Infect Dis J 24(6):563–566. https://doi.org/10.1097/01.inf.0000164708.21464.03
Bochud PY, Eggiman P, Calandra T, van Melle G, Saghafi L, Francioli P (1994) Bacteremia due to viridans Streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 18(1):25–31. https://doi.org/10.1093/clinids/18.1.25
Brunet AS, Ploton C, Galambrun C et al (2006) Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia. Pediatr Blood Cancer (6):47, 765–772
Gassas A, Grant R, Richardson S, Dupuis LL, Doyle J, Allen U, Abla O, Sung L (2004) Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol. 22(7):1222–1227. https://doi.org/10.1200/JCO.2004.09.108
Melo JC, Raff MJ (1978) Brain abscess due to streptococcus MG-intermedius (Streptococcus milleri). J Clin Microbiol 7(6):529–532
Pratter MR, Irwin RS (1980) Viridans streptococci pulmonary parenchymal infections. JAMA 243(24):2515–2517. https://doi.org/10.1001/jama.1980.03300500041027
Sarkar TK, Muraka RS, Gilardi GL (1989) Primary Streptococcus viridans pneumonia. Chest 96(4):831–834. https://doi.org/10.1378/chest.96.4.831
Bartlett JG, Finegold SM (1974) Anaerobic infections of the lung and pleural space. Am Rev Respir Dis. 110(1):56–77
Ringe HIG, Varnholt V, Gaedicke G (2003) Cardiac rescue with enoximone in volume and catecholamine refractory septic shock. Pediatr Crit Care Med 4(4):471–475. https://doi.org/10.1097/01.PCC.0000074275.61913.72
John J, Awab A, Norman D, Dernaika T (2007) Kinasewitz GT. Activated protein C improves survival in severe sepsis patients with elevated troponin, Intensive Care Med
Lamagni TL, Efstratiou A, Vuopio-Varkila J, Jasir A, Schalèn C, Strep-EURO (2005) The epidemiology of severe Streptococcus pyogenes associated disease in Europe. Euro. Surveill. 10(9):179–184. https://doi.org/10.2807/esm.10.09.00563-en
Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, Vuopio-Varkila J, Bouvet A, Creti R, Ekelund K, Koliou M, Reinert RŔ, Stathi A, Strakova L, Ungureanu V, Schalén C, Jasir A (2008) Epidemiology of severe Streptococcus pyogenes disease in Europe. Strep-EURO Study Group, Jasir A. J Clin Microbiol. 46(7):2359–2367. https://doi.org/10.1128/JCM.00422-08
Miyairi I, Berlingieri D, Protic J, Belko J (2004) Neonatal invasive group A streptococcal disease: case report and review of the literature. Pediatr Infect Dis J 23(2):161–165. https://doi.org/10.1097/01.inf.0000109887.40636.07
Demers B, Simor AE, Vellend H, Schlievert PM, Byrne S, Jamieson F, Walmsley S, Low DE (1993) Severe invasive Group A streptococcal infection in Ontario, Canada: 1987-91. Clin Infect Dis 16(6):792–800. https://doi.org/10.1093/clind/16.6.792
Stevens DL (1992) Invasive group A streptococcus infections. Clin Infect Dis 14(1):2–13. https://doi.org/10.1093/clinids/14.1.2
O’Brien KL, Beall B, Barett NL et al (2002) Epidemiology of invasive group A streptococcus disease in the United States, 1995-99. Clin Infect Dis 35(3):268–276. https://doi.org/10.1086/341409
Factor SH, Levine OS, Harrison LH, Farley MM, McGeer A, Skoff T, Wright C, Schwartz B, Schuchat A (2005) Risk factors for pediatric invasive group A streptococcal disease. Emerg Infect Dis 11(6):1062–1066. https://doi.org/10.3201/eid1107.040900
Wilson WC, Benumof JL (2005) Anesthesia for thoracic surgery. In: Miller RD (ed) Miller’s Anesthesia, 6th edn. Elsevier, New York, pp 1887–1889
Kvetan V, Carlon GC, Howland WS (1982) Acute pulmonary failure in asymmetric lung disease: approach to management. Crit Care Med 10(2):114–118. https://doi.org/10.1097/00003246-198202000-00011
Brady KM, Harris ZL, Hammer GB, Berkowitz ID, Easley RB (2005) Lung isolation in a child with unilateral necrotizing Clostridium perfringens pneumonia. Crit Care Med 33(11):2676–2680. https://doi.org/10.1097/01.CCM.0000186776.40271.6A
Choudhry DK (2005) Single-lung ventilation in pediatric anesthesia. Anesthesiol Clin N Am 23(4):693–708. https://doi.org/10.1016/j.atc.2005.07.006
Tobias JD (2001) Variations on one-lung ventilation. J Clin Anesth 13(1):35–39. https://doi.org/10.1016/S0952-8180(00)00230-0
Hammer GB, Fitzmaurice BG, Brodsky JB (1999) Methods for single-lung ventilation in pediatric patients. Anesth Analg 89(6):1426. https://doi.org/10.1213/00000539-199912000-00019
Ethics approval and consent to participate
This study was approved by the Ethical Committee of the Catholic University of Sacred Heart, Rome [Prot. N 0011043/21 of 24/03/2021].
Consent for publication
Verbal informed consent was obtained from legal guardians.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Piastra, M., Ferrari, V., Picconi, E. et al. Life-threatening complications of streptococcal sepsis: a PICU contemporary series. J Anesth Analg Crit Care 1, 24 (2021). https://doi.org/10.1186/s44158-021-00028-1
- Streptococcal sepsis complications
- Intensive care
- Mechanical ventilation
- Septic shock
- Tissue tropism phenotypes